C. Halstenson

发表

Disposition of Guanadrel in Subjects with Normal and Impaired Renal Function

G. Matzke, C. Halstenson, J. Opsahl, 1989, Journal of clinical pharmacology.

Analytical accuracy of determinations of aminoglycoside concentrations by enzyme multiplied immunoassay, fluorescence polarization immunoassay, and radioimmunoassay in the presence of heparin

G. Matzke, C. Halstenson, M. E. O'Connell, 1984, Journal of clinical microbiology.

Heparin Interferes with Tobramycin Serum Concentration Determinations by Emit

G. Matzke, C. Halstenson, P. A. Abraham, 1984, Drug intelligence & clinical pharmacy.

Pharmacokinetics of flutamide in patients with renal insufficiency.

S. Swan, C. Halstenson, E. Radwanski, 1999, British journal of clinical pharmacology.

Correlation of office and ambulatory blood pressure measurements with urinary albumin and N-acetyl-beta-D-glucosaminidase excretions in essential hypertension.

W. Keane, C. Halstenson, J. Opsahl, 1988, American journal of hypertension.

Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.

R. Asinger, A. Collins, C. Halstenson, 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency.

W. Keane, C. Halstenson, J. Opsahl, 1988, Archives of internal medicine.

Analytical specificity of commercially available methods for serum phenytoin determination.

W. Keane, G. Matzke, C. Halstenson, 1984, Journal of analytical toxicology.

Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia.

W. Keane, C. Halstenson, L. Bell, 1992, Archives of internal medicine.

Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease

W. Keane, D. Sica, C. Halstenson, 2000, Clinical pharmacokinetics.

Hemodialysis elimination rates and clearance of gentamicin and tobramycin

W. Keane, G. Matzke, C. Halstenson, 1984, Antimicrobial Agents and Chemotherapy.

Effects of Probenecid and Cimetidine on Renal Disposition of Ofloxacin in Rats

C. Halstenson, E. Foote, 1998, Antimicrobial Agents and Chemotherapy.

Disposition of Gabapentin in Anuric Subjects on Hemodialysis

W. Keane, C. Halstenson, D. Türck, 1995, Journal of clinical pharmacology.

Pharmacokinetics and pharmacodynamics of codeine in end‐stage renal disease

J. W. Findlay, G. Matzke, C. Halstenson, 1988, Clinical pharmacology and therapeutics.

The effect of famotidine on renal function in patients with renal insufficiency.

W. Keane, G. Matzke, C. Halstenson, 1987, British journal of clinical pharmacology.

Improvement in the accuracy and precision of creatinine clearance as a measure of glomerular filtration rate with oral cimetidine in renal transplant recipients

B. Kasiske, C. Halstenson, C. Hirata-Dulas, 1993 .

Gentamicin Disposition in Young and Elderly Patients with Various Degrees of Renal Function

G. Matzke, C. Halstenson, J. J. Jameson, 1987, Journal of clinical pharmacology.

Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.

R. Asinger, C. Halstenson, J. Opsahl, 1990, American journal of nephrology.

Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies

C. Halstenson, J. Opsahl, M. H. Schwenk, 1992, Clinical pharmacology and therapeutics.

Treatment Recommendations 1993 Update

T. Golper, W. Keane, H. Verbrugh, 1993 .

Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis.

T. Golper, W. Keane, H. Verbrugh, 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

The Pharmacokinetics of Quinapril and Its Active Metabolite, Quinaprilat, in Patients with Various Degrees of Renal Function

A. M. Horvath, S. Olson, E. Posvar, 1992, Journal of clinical pharmacology.

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.

B. Kasiske, J. Velosa, W. Keane, 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

New Therapeutic Agents in the Management of Hypertension: Angiotensin II-Receptor Antagonists and Renin Inhibitors

C. Halstenson, E. Foote, 1993, The Annals of pharmacotherapy.

Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta

C. Halstenson, S. Katz, J. Sobota, 1991, Clinical pharmacology and therapeutics.

Recombinant Human Erythropoietin

C. Halstenson, M. H. Schwenk, 1989, DICP : the annals of pharmacotherapy.

Pharmacokinetics of Zileuton and Its Metabolites in Patients with Renal Impairment

R. Hansen, W. Keane, C. Halstenson, 1997, Journal of clinical pharmacology.

Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency.

W. Keane, C. Halstenson, J. Opsahl, 1988, Archives of internal medicine.

Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency.

G. Matzke, C. Halstenson, W. Awni, 1987, Annals of allergy.

Isepamicin disposition in subjects with various degrees of renal function

C. Halstenson, M. Affrime, W. Awni, 1991, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of Codeine After Single‐and Multiple‐Oral‐Dose Administration to Normal Volunteers

J. W. Findlay, G. Matzke, C. Halstenson, 1987, Journal of clinical pharmacology.

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

C. Halstenson, M. Patchen, R. Walsh, 2016, Investigational New Drugs.

Peritonitis and Other Complications

W. Keane, C. Halstenson, 1998 .

Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing

W. Keane, G. Matzke, C. Halstenson, 1989, Antimicrobial Agents and Chemotherapy.

Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis

G. Matzke, C. Halstenson, M. Affrime, 1986, Antimicrobial Agents and Chemotherapy.

The pharmacokinetics of losartan in renal insufficiency

W. Keane, S. Shahinfar, C. Halstenson, 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Disposition of Famotidine in Renal Insufficiency

W. Keane, G. Matzke, C. Halstenson, 1987, Journal of clinical pharmacology.

Pharmacokinetics of vancomycin in patients with various degrees of renal function

W. Keane, G. Matzke, C. Halstenson, 1984, Antimicrobial Agents and Chemotherapy.

Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis.

A. Collins, G. Matzke, C. Halstenson, 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Controversies in Determination of Epoetin (Recombinant Human Erythropoietin) Dosages

W. S. St. Peter, C. Halstenson, P. Abraham, 1992, Clinical pharmacokinetics.

Bumetanide: A New Loop Diuretic (Bumex, Roche Laboratories)

G. Matzke, C. Halstenson, 1983, Drug intelligence & clinical pharmacy.

Clinical Pharmacokinetics of Antibiotics in Patients with Impaired Renal Function

W. S. St. Peter, C. Halstenson, Kimberly A. Redic-Kill, 1992, Clinical pharmacokinetics.

Single‐dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease

J. Haynes, S. Zimmerman, C. Halstenson, 1992, Clinical pharmacology and therapeutics.

Whole-bowel irrigation as a treatment for acute lithium overdose.

C. Halstenson, S. Smith, L. Ling, 1991, Annals of emergency medicine.

Cholesterol-Lowering Effects oHypercholesterolemiain Patients With Mild to Moderate Hypercholesterolemia

W. Keane, C. Halstenson, L. Bell, 1992 .

Disposition of cefmetazole in healthy volunteers and patients with impaired renal function

G. Matzke, C. Halstenson, J. Opsahl, 1990, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis

R. Blevins, G. Matzke, C. Halstenson, 1984, Antimicrobial Agents and Chemotherapy.

Disposition of the cephalosporin cefepime in normal and renally impaired subjects.

G. Matzke, C. Halstenson, J. Opsahl, 1991, Drug metabolism and disposition: the biological fate of chemicals.

Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease

G. Matzke, C. Halstenson, A. Cheryl, 1990, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency

W. Keane, G. Matzke, C. Halstenson, 1991, Antimicrobial Agents and Chemotherapy.

Antihypertensive Therapy with Once‐daily Administration of Terazosin, a New Alpha1‐adrenergic‐receptor Blocker

W. Keane, G. Matzke, C. Halstenson, 1985, Pharmacotherapy.

Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.

W. Keane, G. Matzke, C. Halstenson, 1985, American journal of nephrology.

Pharmacokinetics of Cefotaxime during CAPD

G. Matzke, C. Halstenson, K. Heim, 1986 .

Disposition of roxithromycin in patients with normal and severely impaired renal function

J. Kovarik, G. Matzke, C. Halstenson, 1990, Antimicrobial Agents and Chemotherapy.

Adjunctive therapy with intravenous human immunoglobulin G improves survival of patients with acute renal failure.

W. Keane, C. Dinarello, A. Ney, 1991, Journal of the American Society of Nephrology : JASN.

Pharmacokinetics ofVancomycin inPatients Undergoing Continuous Ambulatory Peritoneal Dialysis

G. Matzke, C. Halstenson, N. Salem, 1984 .

Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients.

A. Collins, S. Swan, W. Colburn, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Validity of creatinine clearance estimates in the assessment of renal function

G. Matzke, C. Halstenson, J. Opsahl, 1990, Clinical pharmacology and therapeutics.

Determination of residual renal function with iohexol clearance in hemodialysis patients.

B. Kasiske, A. Collins, S. Swan, 1996, Kidney international.

Pharmacokinetics of Tazobactam M1 Metabolite After Administration of Piperacillin/Tazobactam in Subjects with Renal Impairment

W. Keane, C. Lathia, K. Tantillo, 1994, Journal of clinical pharmacology.

Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis.

G. Matzke, C. Halstenson, R. Blevins, 1984, Clinical nephrology.

Disposition of Minoxidil in Patients with Various Degrees of Renal Function

G. Matzke, C. Halstenson, J. Opsahl, 1989, Journal of clinical pharmacology.

Pharmacokinetics of Loratadine in Patients with Renal Insufficiency

G. Matzke, C. Halstenson, J. Opsahl, 1990, Journal of clinical pharmacology.

Disposition of Cefpodoxime Proxetil in Hemodialysis Patients

G. S. Hughes, M. Borin, C. Halstenson, 1992, Journal of clinical pharmacology.

Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function

G. S. Hughes, M. Borin, C. Halstenson, 1992, Antimicrobial Agents and Chemotherapy.

Bioavailability of Labetalol in Patients with End‐Stage Renal Disease

G. Matzke, C. Halstenson, J. Opsahl, 1992, Therapeutic drug monitoring.

Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease

W. Keane, C. Halstenson, M. Affrime, 1992 .

The disposition and dynamics of labetalol in patients on dialysis

G. Matzke, C. Halstenson, J. Opsahl, 1986, Clinical pharmacology and therapeutics.

Evaluation of two intravenous single-bolus methods for measuring effective renal plasma flow.

G. Matzke, C. Halstenson, D. Guay, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effect of haemodialysis on the pharmacokinetics of cetirizine

G. Matzke, C. Halstenson, J. Opsahl, 2004, European Journal of Clinical Pharmacology.

Cefotaxime and desacetyl cefotaxime kinetics in renal impairment

W. Keane, G. Matzke, C. Halstenson, 1985, Clinical pharmacology and therapeutics.

The effect of renal disease on ketoprofen disposition

C. Halstenson, W. Cevallos, E. Boyce, 1992 .

Suprofen-induced uricosuria. A potential mechanism for acute nephropathy and flank pain.

W. Keane, G. Matzke, C. Halstenson, 1988, American journal of nephrology.

The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis.

W. Keane, C. Halstenson, P. Giles, 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment.

C. Halstenson, A. Shah, S. Weir, 1998, Journal of clinical pharmacology.

Disposition of Misoprostol and its Active Metabolite in Patients With Normal and Impaired Renal Function

W. Keane, C. Halstenson, A. Karim, 1995, Journal of clinical pharmacology.

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3–1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects

C. Halstenson, M. Patchen, R. Walsh, 2016, Investigational New Drugs.

DISPOSITION OF MISOPROSTOL AND ITS ACTIVE METABOLITE IN IMPAIRED HEPATIC FUNCTION

W. Keane, C. Halstenson, A. Karim, 1994, American journal of therapeutics.

Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

H. Pan, C. Halstenson, J. Triscari, 1992, Journal of clinical pharmacology.

Effect of Ticarcillin on Gentamicin and Tobramycin Pharmacokinetics in a Patient with End‐stage Renal Disease

A. Collins, G. Matzke, C. Halstenson, 1984, Pharmacotherapy.

The Influence of Food on the Bioavailability of a Twice‐Daily Controlled Release Carbamazepine Formulation

C. Halstenson, Yuxin Zhang, R. Couch, 2001, Journal of clinical pharmacology.